Vaxzevria/COVID-19 Vaccine AstraZeneca: Risk of thrombosis in combination with thrombocytopenia - Updated information

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
Active substance
ChAdOx1-SARS-COV-2
Therapeutic area (MeSH)
COVID-19 virus infection
Procedure number
EMEA/H/C/005675/II/0014
Regulatory outcome
Variation
DHPC type
Type II variation
Human ATC code
J07BX03
Dissemination date
02/06/2021

How useful was this page?

Add your rating
Average
3 ratings